Stephen K. Doberstein, SVP & Chief Scientific Officer at NEKTAR THERAPEUTICS (NKTR), sold 100,000 shares at $21.70 ($2.2M) on 2017-04-05, disclosed to the SEC on 2017-04-07.
Open-market sale of $2.2M NKTR by SVP & Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| NKTR | SELL | 2019-05-17 | $217K | — | Filing → |
| NKTR | SELL | 2019-02-21 | $281K | — | Filing → |
| NKTR | SELL | 2018-11-19 | $173K | — | Filing → |